Literature DB >> 6965392

The augmentation of in vitro and in vivo tumor-specific T cell-mediated immunity by amplifier T lymphocytes.

H Fujiwara, T Hamaoka, G M Shearer, H Yamamoto, W D Terry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6965392

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  23 in total

Review 1.  Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state.

Authors:  H Fujiwara; T Hamaoka
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

2.  Enhancement of immunity against RSV-induced sarcomas by generation of hapten-reactive helper T lymphocytes.

Authors:  P M Comoglio; M Prat; S Bretti
Journal:  Immunology       Date:  1985-02       Impact factor: 7.397

3.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.

Authors:  J Shima; T Yoshioka; H Nakajima; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.

Authors:  H Sano; A Kosugi; S Sano; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Augmentation of generation of human allospecific cytotoxic T lymphocyte by PPD in in vitro sensitization culture.

Authors:  R Ohno; Y Kodera; H Yamada
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

6.  Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potential to reconstitute tumor-specific effector T cell clones.

Authors:  H Fujiwara; S Sato; A Kosugi; M Fukuzawa; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.

Authors:  S Sato; H Fujiwara; A Kosugi; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.

Authors:  T Yoshioka; M Fukuzawa; Y Takai; N Wakamiya; S Ueda; S Kato; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.

Authors:  T Hamaoka; Y Takai; A Kosugi; Y Mizushima; J Shima; T Kusama; H Fujiwara
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.

Authors:  A Kosugi; J Shima; H Sano; M Ogata; T Kusama; H Fujiwara; T Hamaoka
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.